<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for extensive-stage small-cell lung cancer: Atezolizumab plus carboplatin and &lt;span style="white-space: nowrap;"&gt;etoposide&lt;sup&gt;[1]&lt;/sup&gt;&lt;/span&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for extensive-stage small-cell lung cancer: Atezolizumab plus carboplatin and <span style="white-space: nowrap;">etoposide<sup>[1]</sup></span></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for extensive-stage small-cell lung cancer: Atezolizumab plus carboplatin and <span style="white-space: nowrap;">etoposide<sup>[1]</sup></span></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 21 days.<br/> <strong>Duration of therapy:</strong> Four cycles plus maintenance atezolizumab monotherapy.</td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td colspan="4"><strong>Induction phase (four cycles)</strong></td> </tr> <tr> <td>Atezolizumab</td> <td>1200 mg IV</td> <td>Dilute in 250 mL <span style="white-space: nowrap;">NS*</span> and administer first dose over 60 minutes; if first infusion is tolerated, then administer subsequent doses over 30 minutes. Administer atezolizumab prior to chemotherapy on days that chemotherapy is given.</td> <td>Day 1</td> </tr> <tr> <td>Carboplatin</td> <td><span style="white-space: nowrap;">AUC<sup>¶</sup></span> = 5 mg/mL × min IV</td> <td>Dilute in 250 mL <span style="white-space: nowrap;">NS*</span> and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> <span style="white-space: nowrap;">IV<sup>Δ</sup></span></td> <td>Dilute in 500 mL <span style="white-space: nowrap;">NS*</span> or D5W to final concentration of &lt;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.</td> <td>Days 1, 2, and 3</td> </tr> <tr> <td colspan="4"><strong>Maintenance phase (until disease progression)</strong></td> </tr> <tr class="divider_bottom"> <td>Atezolizumab</td> <td>1200 mg IV</td> <td>Dilute in 250 mL <span style="white-space: nowrap;">NS*</span> and administer over 30 or 60 minutes depending upon infusion tolerance.</td> <td>Day 1</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>Atezolizumab/carboplatin/etoposide (day 1): MODERATE.</li> <li>Etoposide (days 2 and 3): LOW.</li> <li>Atezolizumab maintenance phase: MINIMAL.</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Atezolizumab can cause severe to life-threatening infusion reactions and may require permanent discontinuation for grade 3 or worse infusion-related <span style="white-space: nowrap;">reaction.<sup>[2]</sup></span></li> <li>For mild infusion reactions, premedication is recommended for subsequent <span style="white-space: nowrap;">infusions.<sup>[1,2]</sup></span></li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Carboplatin and etoposide are irritants.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Routine primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia is approximately <span style="white-space: nowrap;">3%).<sup>[1]</sup></span></li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert <span style="white-space: nowrap;">formula.<sup>¶</sup><sup>[3]</sup></span></li> <li>A lower starting dose of etoposide may be needed for patients with renal or liver <span style="white-space: nowrap;">impairment.<sup>[4]</sup></span></li> <li>Refer to UpToDate topics on dosing of anticancer agents in adults; chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with kidney impairment, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Immune-mediated adverse events or conditions</strong></td> <td colspan="3"> <ul> <li>Anti-PD-L1 monoclonal antibodies generate an immune response that may aggravate underlying autoimmune disorders or prior immune-related adverse events. There are only limited data on the safety and efficacy of checkpoint inhibitors such as atezolizumab in patients with an underlying autoimmune disorder.<sup>[5]</sup> Atezolizumab should be used with extreme caution in such individuals. Individual evaluation is required for use of existing immunosuppression agents.</li> <li>Refer to UpToDate topics on toxicities associated with checkpoint inhibitor immunotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Severe or life-threatening infections</strong></td> <td colspan="3"> <ul> <li>Atezolizumab can cause severe and/or life-threatening infections.</li> <li>Withhold or discontinue atezolizumab for severe <span style="white-space: nowrap;">infections.<sup>[2]</sup></span></li> <li>Refer to UpToDate topics on toxicities associated with checkpoint inhibitor immunotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Thyroid function tests</strong></td> <td colspan="3"> <ul> <li>Assess baseline thyroid function tests (TSH, FT4) prior to initiation of therapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Regulatory issues</strong></td> <td colspan="3"> <ul> <li>An FDA-approved patient medication guide, which is available with the United States Prescribing <span style="white-space: nowrap;">Information,<sup>[6]</sup></span> must be dispensed with atezolizumab.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count weekly during induction treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Electrolytes and liver and renal function prior to each cycle of induction chemotherapy, and liver function tests every one to two cycles, and as clinically indicated, during maintenance atezolizumab.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess thyroid function tests and blood glucose every one to two cycles during treatment (both induction and maintenance) and/or as clinically indicated.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for infusion reactions.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs and symptoms of immune-mediated adverse events (eg, colitis, diarrhea, hepatitis, hypophysitis, adrenal insufficiency, thyroid disorders, infection, cardiovascular, pneumonitis, renal, dermatologic, neurologic, ocular toxicity, etc).</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Per protocol, at the beginning of each cycle, the ANC should be ≥1500/microL and platelets ≥100,000/microL. Cycles can be delayed for up to 42 days to allow sufficient time for count recovery. Reduce carboplatin dose by 25% for any platelet count &lt;25,000/microL or ANC &lt;500/microL and platelets ≥50,000/microL, or for ANC &lt;1000/microL with a temperature <span style="white-space: nowrap;">&gt;38.5°C.<sup>[1]</sup></span> Reduce carboplatin dose by 50% for platelets &lt;50,000/microL: with grade ≥2 bleeding, regardless of ANC. These dose reductions should be maintained for the remainder of induction therapy. Colony-stimulating factors may be used instead of dose reduction for neutropenic fever or grade 4 neutropenia.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Nonhematologic toxicity</strong></td> <td colspan="3"> <ul> <li>Chemotherapy should be held for grade 3 or 4 nonhematologic toxicities and only restarted after the toxicity has resolved to patient's <span style="white-space: nowrap;">baseline.<sup>[1]</sup></span> Once recovered, a 25% dose reduction of carboplatin is recommended for grade 3 or 4 oral mucositis, nausea/vomiting (despite optimal antiemetics), neurotoxicity, or grade 3 transaminase elevation. Discontinue carboplatin for grade 4 transaminase elevation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="3"> <ul> <li>No formal etoposide dosing recommendations were provided in the <span style="white-space: nowrap;">protocol.<sup>[1]</sup></span> However, accepted dose reductions per product information may be found in the literature.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Nephrotoxicity</strong></td> <td colspan="3"> <ul> <li>While a 25% dose reduction for initial dosing of etoposide is recommended for CrCl of 15 to 50 mL/min, further dose reduction may be needed for more severe renal dysfunction; the protocol recommended a 25% dose reduction for a decline in the CrCl during <span style="white-space: nowrap;">treatment.<sup>[1,4]</sup></span></li> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose.</li> <li>Refer to UpToDate topics on chemotherapy nephrotoxicity and dose modification in patients with kidney impairment, conventional cytotoxic agents and dosing of anticancer agents in adults.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Immune-mediated adverse</strong> <span style="white-space: nowrap;"><strong>events<sup>[1,2]</sup></strong></span></td> <td colspan="3"> <ul> <li>Dose reductions of atezolizumab are not recommended; treatment is withheld or discontinued to manage toxicities.<sup>[1,2,6]</sup></li> <li>In general, if an immune-mediated adverse event is suspected, evaluate appropriately to confirm or exclude other causes. Based on the type and severity of the reaction, withhold treatment and administer systemic glucocorticoids. Upon resolution to ≤grade 1, initiate glucocorticoid taper. Immune-mediated adverse reactions that do not resolve with systemic glucocorticoids may be managed with other systemic immunosuppressants (based on limited data). Discontinue atezolizumab permanently for any grade 4 or recurrent grade 3 immune-mediated adverse event or one that is life threatening, grade 3 pneumonitis, AST/ALT elevation &gt;8 times ULN, total bilirubin elevation &gt;3 times ULN in patients with no hepatic tumor involvement, AST/ALT elevation to &gt;10 times ULN for hepatitis with hepatic tumor involvement, grade ≥2 myocarditis, grade 3 neurologic toxicity, suspected exfoliative dermatologic condition, severe (grade 3) or life-threatening (grade 4) infusion reactions, or if there is an inability to reduce glucocorticoid dose to 10 mg or less of prednisone equivalent per day within 12 weeks of initiating glucocorticoids.<sup>[6]</sup></li> <li>Guidelines for managing specific toxicities, including immune-mediated adverse events, are available in the United States Prescribing Information for atezolizumab,<sup>[6]</sup> from ASCO,<sup>[2]</sup> from the MASCC,<sup>[7]</sup> from the NCCN,<sup>[8] </sup>and from the SITC.<sup>[9]</sup></li> <li>Refer to UpToDate topics on toxicities associated with checkpoint inhibitor immunotherapy.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of antineoplastic therapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; AUC: area under the concentration × time curve; D5W: 5% dextrose in water; PD-L1: programmed cell death ligand 1; TSH: thyroid-stimulating hormone; FT4: free thyroxine; FDA: US Food and Drug Administration; CBC: complete blood count; ANC: absolute neutrophil count; C: Celsius; CrCl: creatinine clearance; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; ASCO: American Society of Clinical Oncology; MASCC: Multinational Association of Supportive Care in Cancer; NCCN: National Comprehensive Cancer Network; SITC: Society for Immunotherapy of Cancer; GFR: glomerular filtration rate.<br/>
* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert <font style="white-space: nowrap;">formula.<sup>[3]</sup></font> The Calvert Formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on "Dosing of anticancer agents in adults".<br/>
Δ Although the trial examining this regimen used etoposide 100 mg/m<sup>2</sup>, many experts in practice use 80 mg/m<sup>2</sup>, due to tolerability concerns.</div><div class="graphic_reference">References:
<ol><li>Horn L, et al. N Engl J Med 2018; 379:2220.</li><li>Schneider BJ, et al. J Clin Oncol 2021.</li><li>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 10, 2020).</li><li>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/index.cfm" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 10, 2020).</li><li>Pantuck M, et al. Cancer 2019; 125:3506.</li><li>Atezolizumab. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/index.cfm" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 10, 2020).</li><li>MASCC 2020 clinical practice recommendations for the management of immune-mediated adverse events from checkpoint inhibitors. (Available online at <a href="https://link.springer.com/journal/520/topicalCollection/AC_c9dc4afd8c5d6799b830394e9758cad9" target="_blank">link.springer.com/journal/520/topicalCollection/AC_c9dc4afd8c5d6799b830394e9758cad9</a>, accessed on January 26, 2021).</li><li>NCCN guidelines for management of immunotherapy-related toxicities. (Available online at <a href="https://www.nccn.org" target="_blank">nccn.org</a>, accessed on June 21, 2021).</li><li>SITC cancer immunotherapy guidelines. (Available online at <a href="https://sitcancer.org/research/cancer-immunotherapy-guidelines" target="_blank">sitcancer.org/research/cancer-immunotherapy-guidelines</a>, accessed on March 10, 2022).</li></ol></div><div id="graphicVersion">Graphic 128076 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
